

Tharick Ali Pascoal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1944203/publications.pdf>

Version: 2024-02-01

132
papers

5,017
citations

126907

33
h-index

110387

64
g-index

152
all docs

152
docs citations

152
times ranked

4611
citing authors

#	ARTICLE	IF	CITATIONS
1	Direct Comparison of the Tau PET Tracers ¹⁸ F-Flortaucipir and ¹⁸ F-MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116.	5.0	39
2	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 788-801.	4.3	8
3	¹⁸ F-MK-6240 tau-PET in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1763-1772.	7.6	17
4	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	2.3	44
5	Impact of long- and short-range fibre depletion on the cognitive deficits of fronto-temporal dementia. <i>ELife</i> , 2022, 11, .	6.0	7
6	Mitochondrial complex I abnormalities underlie neurodegeneration and cognitive decline in Alzheimer's disease. <i>European Journal of Neurology</i> , 2022, 29, 1324-1334.	3.3	8
7	Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer's disease. <i>EBioMedicine</i> , 2022, 76, 103836.	6.1	65
8	Comparing tau status determined via plasma pTau181, pTau231 and [¹⁸ F]MK6240 tau-PET. <i>EBioMedicine</i> , 2022, 76, 103837.	6.1	34
9	Association of locus coeruleus integrity with Braak stage and neuropsychiatric symptom severity in Alzheimer's disease. <i>Neuropsychopharmacology</i> , 2022, 47, 1128-1136.	5.4	30
10	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. <i>Nature Aging</i> , 2022, 2, 526-535.	11.6	73
11	Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. <i>Nature Reviews Neurology</i> , 2022, 18, 400-418.	10.1	99
12	Quantification of SNAP-25 with mass spectrometry and Simoa: a method comparison in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	6.2	11
13	Staging of Alzheimer's disease: past, present, and future perspectives. <i>Trends in Molecular Medicine</i> , 2022, 28, 726-741.	6.7	36
14	APOE ϵ 4 potentiates the relationship between amyloid- β 2 and tau pathologies. <i>Molecular Psychiatry</i> , 2021, 26, 5977-5988.	7.9	51
15	Amyloid-beta modulates the association between neurofilament light chain and brain atrophy in Alzheimer's disease. <i>Molecular Psychiatry</i> , 2021, 26, 5989-6001.	7.9	28
16	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. <i>Biological Psychiatry</i> , 2021, 89, 776-785.	1.3	30
17	Determining Amyloid- β 2 Positivity Using ¹⁸ F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252.	5.0	65
18	Topographic Distribution of Amyloid- β 2, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. <i>Neurology</i> , 2021, 96, e81-e92.	1.1	31

#	ARTICLE	IF	CITATIONS
19	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. <i>Molecular Psychiatry</i> , 2021, 26, 429-442.	7.9	186
20	Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 1.	8.0	23
21	Association between regional tau pathology and neuropsychiatric symptoms in aging and dementia due to Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12154.	3.7	19
22	Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. <i>Acta Neuropathologica</i> , 2021, 141, 709-724.	7.7	285
23	Elderly Man Repeating Questions about Upcoming Appointments. , 2021, , 14-17.		0
24	Plasma pTau181 predicts cortical brain atrophy in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 69.	6.2	34
25	Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer's disease. <i>Translational Psychiatry</i> , 2021, 11, 251.	4.8	112
26	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. <i>Brain Communications</i> , 2021, 3, fcab073.	3.3	15
27	Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2021, 16, 28.	10.8	32
28	Interactive rather than independent effect of <i>APOE</i> and sex potentiates tau deposition in women. <i>Brain Communications</i> , 2021, 3, fcab126.	3.3	15
29	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2295-2305.	6.4	41
30	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	12.8	219
31	Association of plasma P-tau181 with memory decline in non-demented adults. <i>Brain Communications</i> , 2021, 3, fcab136.	3.3	33
32	Microglial activation and tau propagate jointly across Braak stages. <i>Nature Medicine</i> , 2021, 27, 1592-1599.	30.7	235
33	Author Response: Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ϵ 4, and Cognitive Impairment. <i>Neurology</i> , 2021, 97, 609-609.	1.1	2
34	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. <i>Brain</i> , 2021, 144, 3517-3528.	7.6	47
35	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, <i>APOE</i> ϵ 4, and Cognitive Impairment. <i>Neurology</i> , 2021, 96, e975-e985.	1.1	42
36	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. <i>Journal of Nuclear Medicine</i> , 2021, 62, 614-619.	5.0	21

#	ARTICLE	IF	CITATIONS
37	Amyloid- β dependent and amyloid- β independent effects of Tau in individuals without dementia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2083-2092.	3.7	7
38	Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum. <i>JAMA Neurology</i> , 2021, 78, 1471.	9.0	204
39	Soluble amyloid-beta isoforms predict downstream Alzheimer's disease pathology. <i>Cell and Bioscience</i> , 2021, 11, 204.	4.8	5
40	Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
41	Associations between neutrophils and amyloid deposition in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
42	Association of tau pathology and vascular risk factor burden with longitudinal measures of plasma neurofilament light. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
43	Verbal fluency associated with tau accumulation and not amyloid deposition in the Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
44	Plasma p-tau181 and p-tau231 offer complementary information to identify Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	1
45	Microglial activation and tau propagate jointly across Braak stages. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	4
46	Profiling tau accumulation with SPReAD: Sub-stages for propagation regions in Alzheimer's disease.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e054239.	0.8	0
47	Suicidal ideation is common in autosomal dominant Alzheimer's disease at-risk persons. <i>International Journal of Geriatric Psychiatry</i> , 2020, 35, 60-68.	2.7	4
48	Association of Apolipoprotein E ϵ 4 With Medial Temporal Tau Independent of Amyloid- β . <i>JAMA Neurology</i> , 2020, 77, 470.	9.0	154
49	¹⁸ F-MK-6240 PET for early and late detection of neurofibrillary tangles. <i>Brain</i> , 2020, 143, 2818-2830.	7.6	147
50	Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease. <i>Brain</i> , 2020, 143, 3793-3804.	7.6	60
51	Impact of p-tau181 and p-tau217 levels on enrollment for randomized clinical trials and future use of anti-amyloid and anti-tau drugs. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1211-1213.	2.8	5
52	Topographical distribution of A β predicts progression to dementia in A β positive mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12037.	2.4	7
53	Mild behavioral impairment is associated with β -amyloid but not tau or neurodegeneration in cognitively intact elderly individuals. <i>Alzheimer's and Dementia</i> , 2020, 16, 192-199.	0.8	102
54	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. <i>Lancet Neurology</i> , The, 2020, 19, 422-433.	10.2	668

#	ARTICLE	IF	CITATIONS
55	Frontal Variant of Alzheimer Disease Differentiated From Frontotemporal Dementia Using in Vivo Amyloid and Tau Imaging. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 288-293.	0.9	6
56	Cholinergic dysfunction in the dorsal striatum promotes habit formation and maladaptive eating. <i>Journal of Clinical Investigation</i> , 2020, 130, 6616-6630.	8.2	29
57	Plasma neurofilament light associates with Alzheimer's disease metabolic decline in amyloid- β positive individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 679-689.	2.4	48
58	Rostral-Caudal Hippocampal Functional Convergence Is Reduced Across the Alzheimer's Disease Spectrum. <i>Molecular Neurobiology</i> , 2019, 56, 8336-8344.	4.0	6
59	$\text{A}\beta$ -induced vulnerability propagates via the brain's default mode network. <i>Nature Communications</i> , 2019, 10, 2353.	12.8	58
60	ICP-168: ISSUES REGARDING [¹⁸ F]MK6240 REFERENCE REGION SELECTION BASED ON THE FULL KINETIC MODELING. <i>Alzheimer's and Dementia</i> , 2019, 15, P132.	0.8	0
61	ICP-180: PREDICTING TAU PATHOLOGY PROGRESSION IN ALZHEIMER'S DISEASE BY MATHEMATICAL SIMULATION: FURTHER RESULTS AND PRIORITIZATION OF MODIFICATIONS FOR FURTHER IMPROVEMENTS. <i>Alzheimer's and Dementia</i> , 2019, 15, P141.	0.8	0
62	ICP-132: CORTICAL IRON DEPOSITION IN ALZHEIMER'S DISEASE CONTRASTS WITH AGE-RELATED SUBCORTICAL DEPOSITION. <i>Alzheimer's and Dementia</i> , 2019, 15, P108.	0.8	0
63	Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [¹⁸ F]THK5351 uptake in progressive supranuclear palsy. <i>NeuroImage: Clinical</i> , 2019, 24, 102091.	2.7	21
64	Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 610-617.	3.7	32
65	Regional Amyloid- β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2019, 56, 4916-4924.	4.0	21
66	A simplified radiosynthesis of [¹⁸ F]MK6240 for tau PET imaging. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 109-114.	1.0	8
67	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S23-S31.	2.6	11
68	CYP2C19 variant mitigates Alzheimer disease pathophysiology in vivo and postmortem. <i>Neurology: Genetics</i> , 2018, 4, e216.	1.9	8
69	Proximity to Parental Symptom Onset and Amyloid- β Burden in Sporadic Alzheimer Disease. <i>JAMA Neurology</i> , 2018, 75, 608.	9.0	19
70	Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1021-1030.	6.4	24
71	Anosognosia predicts default mode network hypometabolism and clinical progression to dementia. <i>Neurology</i> , 2018, 90, e932-e939.	1.1	54
72	Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer's Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 463-472.	1.5	41

#	ARTICLE	IF	CITATIONS
73	Characterizing biomarker features of cognitively normal individuals with ventriculomegaly. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 12-21.	2.4	9
74	O3â€Pâ€04: CORRELATION BETWEEN CSF Tâ€TAU AND Pâ€TAU WITH [¹⁸ F]MK6240 IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1009.	0.8	0
75	P3â€338: AMYLOID AND MICROGLIAL ACTIVATION SYNERGY LEADS TO HYPOMETABOLISM IN AD BRAIN: MICROPET LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P1211.	0.8	0
76	P1â€482: ASSOCIATION OF [¹⁸ F]MK6240 PET TAU BINDING WITH CLINICAL DIAGNOSIS, APOE4, COGNITION, AMYLOID, AGE, AND BRAAK STAGES ACROSS THE AD CLINICAL SPECTRUM. Alzheimer's and Dementia, 2018, 14, P510.	0.8	0
77	P2â€462: UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXELâ€WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS. Alzheimer's and Dementia, 2018, 14, P898.	0.8	0
78	ICâ€Pâ€05: IMAGING EPIGENETICS IN THE HUMAN BRAIN WITH THE NOVEL [¹¹ C]MARTINOSTAT PET IN PRECLINICAL AD, MCI, AD, AND FRONTOTEMPORAL DEMENTIA INDIVIDUALS. Alzheimer's and Dementia, 2018, 14, P9.	0.8	3
79	ICâ€Pâ€022: LATERAL TEMPORAL AMYLOID LOAD PREDICTS PROGRESSION TO ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P28.	0.8	0
80	O3â€10â€06: BRAIN EPIGENETIC CHANGES MEASURED WITH THE NOVEL [¹¹ C]MARTINOSTAT PET MEDIATE THE EFFECTS OF AMYLOID AND TAU PET DEPOSITION ON COGNITION. Alzheimer's and Dementia, 2018, 14, P1045.	0.8	1
81	P2â€503: COGNITIVE PERFORMANCE FOR VERBAL MEMORY AND SEMANTIC VERBAL FLUENCY AS A FUNCTION OF TAU PROTEIN LEVELS. Alzheimer's and Dementia, 2018, 14, P923.	0.8	0
82	ICâ€Pâ€055: REGIONAL PATTERNS OF TAU DEPOSITION DRIVEN BY LOCAL AMYLOID ACCUMULATION RECAPITULATE BRAAK STAGES IN AD. Alzheimer's and Dementia, 2018, 14, P52.	0.8	0
83	ICâ€Pâ€023: UNBIASED ASSESSMENT OF GLOBAL AMYLOID LOAD AS DETERMINED BY VOXELâ€WISE RECEIVER OPERATING CHARACTERISTIC ANALYSIS. Alzheimer's and Dementia, 2018, 14, P29.	0.8	0
84	P2â€353: THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION. Alzheimer's and Dementia, 2018, 14, P823.	0.8	0
85	P1â€148: THE EFFECT OF PROTON PUMP INHIBITORS AND <i>CYP2C19</i> ON AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P333.	0.8	0
86	ICâ€Pâ€063: THE EFFECT OF PROTON PUMP INHIBITORS AND CYP2C19 ON AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P58.	0.8	0
87	ICâ€Pâ€064: THE IMPACT OF TSPO RS6971 POLYMORPHISM IN A CANADIAN NEUROIMAGING STUDY OF NEUROINFLAMMATION. Alzheimer's and Dementia, 2018, 14, P58.	0.8	0
88	P1â€342: SUICIDAL IDEATION IS PREVALENT IN BOTH ASYMPTOMATIC AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE MUTATION AND NONâ€MUTATION CARRIERS. Alzheimer's and Dementia, 2018, 14, P424.	0.8	0
89	ICâ€Pâ€213: [¹⁸ F]MK6240 PET TAU BINDING IN ATYPICAL AD AND NONâ€AD TAUOPATHIES. Alzheimer's and Dementia, 2018, 14, P174.	0.8	0
90	ICâ€Pâ€208: CORRELATION BETWEEN CSF Tâ€TAU AND Pâ€TAU WITH [¹⁸ F]MK6240 IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P171.	0.8	0

#	ARTICLE	IF	CITATIONS
91	P3â€œ441: LOGICAL MEMORY DEFICITS ACROSS ALZHEIMER'S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF A TAU PROPAGATION PREDICTED BY BRAAK STAGING. Alzheimer's and Dementia, 2018, 14, P1283.	0.8	0
92	ICâ€œPâ€œ103: LOGICAL MEMORY DEFICITS ACROSS ALZHEIMER'S DISEASE SPECTRUM ARE ASSOCIATED WITH PATTERNS OF TAU PROPAGATION PREDICTED BY BRAAK STAGING. Alzheimer's and Dementia, 2018, 14, P89.	0.8	0
93	ICâ€œPâ€œ054: AMYLOID AND MICROGLIAL ACTIVATION SYNERGY LEADS TO HYPOMETABOLISM IN THE AD BRAIN: MICROPET LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P51.	0.8	0
94	P4â€œ107: REGIONAL PATTERNS OF TAU DEPOSITION DRIVEN BY LOCAL AMYLOID ACCUMULATION RECAPITULATE BRAAK STAGES IN AD. Alzheimer's and Dementia, 2018, 14, P1479.	0.8	0
95	P1â€œ486: LATERAL TEMPORAL AMYLOID LOAD PREDICTS THE PROGRESSION TO ALZHEIMER'S DEMENTIA. Alzheimer's and Dementia, 2018, 14, P513.	0.8	0
96	Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimerâ€™s disease. Translational Neurodegeneration, 2018, 7, 23.	8.0	43
97	In vivo quantification of neurofibrillary tangles with [18F]MK-6240. Alzheimer's Research and Therapy, 2018, 10, 74.	6.2	120
98	Impact of the biological definition of Alzheimerâ€™s disease using amyloid, tau and neurodegeneration (ATN): what about the role of vascular changes, inflammation, Lewy body pathology?. Translational Neurodegeneration, 2018, 7, 12.	8.0	27
99	Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 80.	6.2	55
100	Clinical Meaningfulness of Biomarker Endpoints in Alzheimerâ€™s Disease Research. Neuromethods, 2018, , 235-248.	0.3	0
101	Amyloid-Î² and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimerâ€™s disease. Molecular Psychiatry, 2017, 22, 306-311.	7.9	105
102	Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimerâ€™s Disease. IEEE Transactions on Medical Imaging, 2017, 36, 1758-1768.	8.9	85
103	Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 2017, 88, 1814-1821.	1.1	61
104	The prevalence and biomarkersâ€™ characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 107-113.	3.7	16
105	Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimer's and Dementia, 2017, 13, 644-653.	0.8	79
106	Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease. Neurology, 2017, 89, 1931.2-1931.	1.1	0
107	Identifying incipient dementia individuals using machine learning and amyloid imaging. Neurobiology of Aging, 2017, 59, 80-90.	3.1	85
108	Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimer's Research and Therapy, 2017, 9, 25.	6.2	285

#	ARTICLE	IF	CITATIONS
109	[P4â€“050]: GRAPHâ€“THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION. Alzheimer's and Dementia, 2017, 13, P1275.	0.8	1
110	[ICâ€“Pâ€“017]: VOXELâ€“WISE DETERMINATION OF SENSITIVITY, SPECIFICITY, AND THRESHOLDS FOR AMYLOID POSITIVITY USING [¹⁸ F]FLORBETAPIR PET. Alzheimer's and Dementia, 2017, 13, P20.	0.8	0
111	[ICâ€“Pâ€“034]: GRAPHâ€“THEORY ANALYSIS SHOWS A HIGHLY EFFICIENT BUT REDUNDANT NETWORK IN MCI TAU PROPAGATION. Alzheimer's and Dementia, 2017, 13, P30.	0.8	0
112	Wrappers Feature Selection in Alzheimer's Biomarkers Using kNN and SMOTE Oversampling. TeMa, 2017, 18, 15.	0.1	4
113	Imaging Alzheimer's disease pathophysiology with PET. Dementia E Neuropsychologia, 2016, 10, 79-90.	0.8	33
114	VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis. Frontiers in Neuroinformatics, 2016, 10, 20.	2.5	73
115	ICâ€“Pâ€“027: Amyloidâ€“Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P28.	0.8	0
116	P1â€“251: Synergism between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€“Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P504.	0.8	0
117	ICâ€“Pâ€“099: Synergism Between Brain Amyloid Accumulation and Neuronal Injury in Corticalâ€“Subcortical Circuits Causes Memory Declines in Animal Models. Alzheimer's and Dementia, 2016, 12, P75.	0.8	0
118	IC-P-101: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in AD Transgenic Rat Model. , 2016, 12, P77-P77.		0
119	P3â€“221: Synergism Between Baseline Amyloidosis and Neuronal Injury as Determinants of Learning Deficits in Alzheimer's Disease Transgenic Rat Model. Alzheimer's and Dementia, 2016, 12, P910.	0.8	0
120	P2-053: Amyloid-Induced Microglial Activity in Thalamocortical Circuits Predicts Subsequent Cognitive Decline. , 2016, 12, P627-P628.		0
121	P3-133: Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study. , 2015, 11, P674-P675.		0
122	P4-035: Cerebrospinal fluid ad biomarkers predict poorer cognitive performance in a cognitively intact cohort at risk of Alzheimer's dementia: The prevent-ad program. , 2015, 11, P778-P779.		0
123	P4-097: Should a global or a regional measure of amyloidosis be used in a longitudinal study?. , 2015, 11, P811-P811.		0
124	Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimerâ€™s disease. Scientific Data, 2015, 2, 150043.	5.3	30
125	Epistasis analysis links immune cascades and cerebral amyloidosis. Journal of Neuroinflammation, 2015, 12, 227.	7.2	10
126	IC-P-154: Association between apolipoprotein a-i levels and white matter hyperintensities depends on CSF tau levels in a high-risk cohort of aging cognitively normal persons: The prevent-alzheimer's disease study. , 2015, 11, P103-P103.		2

#	ARTICLE	IF	CITATIONS
127	IC-P-155: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24-months follow-up in cognitively normal subjects. , 2015, 11, P104-P104.		0
128	O5-01-06: Baseline CSF p-tau and fibrillary amyloid load predict mesial temporal hypometabolism in 24 months' follow-up in cognitively normal subjects. , 2015, 11, P314-P315.		0
129	Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy. Case Reports in Oncological Medicine, 2013, 2013, 1-3.	0.3	15
130	Posterior Reversible Encephalopathy Syndrome Following a Scorpion Sting. Journal of Neuroimaging, 2013, 23, 535-536.	2.0	16
131	Immediate improvement of motor function after epilepsy surgery in congenital hemiparesis. Epilepsia, 2013, 54, e109-11.	5.1	11
132	Bilateral perisylvian ulegyria: An underâ€recognized, surgically remediable epileptic syndrome. Epilepsia, 2013, 54, 1360-1367.	5.1	10